BRC praises DOJ and DEA’s statement to move cannabis production for research forward

George Hodgin, CEO of Biopharmaceutical Research Company (BRC) has issued the following statement lauding the Drug Enforcement Administration’s (DEA) announcement that it will begin processing applications to cultivate cannabis for research purposes:

“The DEA’s announcement that it will process applications to cultivate cannabis for research use is great news for scientists, health care providers, patients, and regulatory authorities. I started BRC with a dream of helping my fellow veterans use cannabis to treat their wartime wounds. The processing of these applications brings BRC one step closer to helping my fellow veterans find relief for their chronic pain, anxiety, depression, post-traumatic stress and other illnesses. The entire BRC team stands ready to work with the DEA throughout this process and we are eager to get to work.” Read more →